Clinical trials: Neoplasm Recurrence
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
HGG, High Grade Glioma (III or IV)
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
- Conditions
- HGG, High Grade Glioma (III or IV), High Grade Glioma
- Trial name
- NCT07710690
- Testing
- NRG-103
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Neuregen Therapeutics Co., Ltd.
Pilonidal Sinus
Study on Surgical Treatment of Pilonidal Sinus Disease
Comparison of limited excision-primary closure, Limberg, and modified Limberg flap techniques for the surgical treatment of pilonidal sinus disease, each performed by a separate surgeon, in terms of postoperative outcomes and…
- Trial name
- NCT02849197
- Testing
- surgery for pilonidal sinus disease
- Volunteers
- 802 people
- Sponsor
- Bezmialem Vakif University
Multiple Myeloma
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM.
- Trial name
- NCT05594797
- Testing
- Human BCMA Targeted T Cells Injection
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
purpose Primary endpoint To evaluate the 24 month disease free survival Second endpoints To evaluate the 24 month overall survival To analyze the toxicity and the quality of life
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01570582
- Testing
- carboplatin and paclitaxel
- Where
- South Korea
- Volunteers
- 314 people
- Sponsor
- Korean Gynecologic Oncology Group
Lymphoma, Metastatic Malignant Solid Neoplasm
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
This phase Ib trial studies the side effects and best dose of copanlisib and nivolumab and side effects of copanlisib given together with nivolumab and ipilimumab in treating patients with solid tumors that may have spread from…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT03502733
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Melanoma (Skin)
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003747
- Testing
- carboplatin, temozolomide
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Malignant Melanoma
Anesthesia and Cancer Recurrence im Malignant Melanoma
Studies in animals and retrospective studies in humans show that regional anesthesia reduces metastatic cancer dissemination. The investigators hypothesize that in patients suffering from malignant melanoma who have to undergo…
- Trial name
- NCT01588847
- Testing
- Spinal anesthesia with Bupivacaine hyperbar 0.5 %, General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- University Hospital Muenster
Ovarian Cancer
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
This study aims to test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression…
- Trial name
- MITO-8 (NCT00657878)
- Testing
- stealth liposomal doxorubicin, carboplatin, paclitaxel
- Where
- 40 sites in Belgium, Germany and 1 more
- Volunteers
- 215 people
- Sponsor
- National Cancer Institute, Naples
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
- Trial name
- NCT00948389
- Testing
- Dasatinib, Lomustine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Bristol-Myers Squibb
Endometrial Cancer
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for…
- Trial name
- NCT06321068
- Testing
- carboplatin, Paclitaxel, Recombinant humanized anti-PD-1 monoclonal antibody injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed).
- Trial name
- NCT04905810
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brian Jonas
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make…
- Trial name
- NCT00004038
- Testing
- Ad5CMV-p53 gene, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hernia, Hiatal, Laparoscopic
Laparoscopic Primary Diaphragm Versus Mesh Repair for Hiatus Hernia: a Long-Term Follow-Up
Assessment of the recurrence of hiatal hernia five to ten years after repair using sutures versus sutures reinforced with non-absorbable mesh.
- Conditions
- Hernia, Hiatal, Laparoscopic, Surgery, Recurrence
- Trial name
- PRIME LTFU (NCT05662735)
- Testing
- Mesh repair, Suture repair
- Volunteers
- 60 people
- Sponsor
- Rijnstate Hospital
Large Hiatal Hernia
Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia
The large hiatal hernia (LHH) now represents approximately 50% of laparoscopic antireflux surgical practice. In a non-comparative retrospective study of 399 patients operated for LHH with onlay patch of a bioprosthetic absorbable…
- Trial name
- HIATUS (NCT05867225)
- Testing
- Laparoscopic hiatal hernia repair
- Where
- 26 sites in France
- Volunteers
- 256 people
- Sponsor
- University Hospital, Bordeaux
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
This study is a single-arm, multicenter, Phase II study to evaluate the efficacy and safety of the treatment of Serplulimab plus Bevacizumab in combination with chemotherapy in 1L treatment of patients with untreated recurrent or…
- Trial name
- NCT05444374
- Testing
- Serplulimab, Bevacizumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.